- In March 2024, Zoetis Inc., a global leader in animal health, announced the launch of an enhanced veterinary tetracycline formulation designed to improve efficacy and reduce withdrawal periods in food-producing animals. This new product underscores Zoetis’s commitment to advancing antibiotic solutions that align with regulatory requirements and promote animal welfare. The launch aims to address increasing demand for effective disease management while supporting sustainable livestock production
- In February 2024, Elanco Animal Health Incorporated expanded its veterinary antibiotic portfolio with the introduction of a novel tetracycline-based treatment targeting respiratory infections in cattle and swine. This advancement reflects Elanco’s focus on addressing growing concerns around antibiotic resistance through innovative formulation strategies and responsible use guidelines
- In January 2024, Boehringer Ingelheim Animal Health announced a collaboration with agricultural research institutes in Europe to conduct extensive field trials evaluating the efficacy of tetracycline antibiotics in poultry. This initiative highlights the company’s commitment to scientific research and development aimed at optimizing veterinary treatments in line with evolving industry standards
- In December 2023, Phibro Animal Health Corporation reported a strategic partnership with feed manufacturers to integrate veterinary tetracycline products into animal nutrition programs. This collaboration seeks to enhance disease prevention strategies and improve overall animal health management in commercial farming operations globally
- In November 2023, Huvepharma AD launched a new veterinary tetracycline injectable formulation approved in multiple emerging markets, aiming to increase accessibility and affordability of effective antibiotics for livestock producers. This development reflects Huvepharma’s strategy to expand its global footprint in the veterinary pharmaceutical sector
